Author

Brian Bressler 1

1 University of British Columbia,Vancouver,Canada

Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler, Andres Yarur, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Sumit Saha, Christina Kifnidi, Dirk Demuth, Haridarshan Patel, Gerassimos J. Mantzaris

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

IMPACT OF CONCOMITANT IMMUNOMODULATOR TREATMENT ON EFFICACY AND SAFETY OF ANTI-TNF THERAPY IN CROHN’S DISEASE: A META-ANALYSIS OF PLACEBO CONTROLLED TRIALS WITH INDIVIDUAL PATIENT-LEVEL DATA

Jennifer Jones, Laurent Peyrin-Biroulet, L Baidoo, Shane Devlin, Gil Y. Melmed, D Tanyingoh, L Raffals, Peter Irving, Patricia Kozuch, Miles P. Sparrow, Fernando Velayos, Brian Bressler, A Cheifetz, Jean-Frederic Colombel, Corey A Siegel, Gilaad G. Kaplan

PTG-100, AN ORAL GUT-RESTRICTED PEPTIDE α4β7 ANTAGONIST, INDUCES CLINICAL AND HISTOLOGIC REMISSION IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS

William Sandborn, Brian Bressler, Scott D. Lee, Raj Bhandari, Bittoo Kanwar, Lucio Tozzi, Richard Shames, Geert R. D'Haens, Jean-Frederic Colombel, Stefan Schreiber, Silvio Danese, Rish K. Pai, Brian G. Feagan

Real-world Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results from the EVOLVE study

Andres Yarur, Gerassimos J. Mantzaris, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Christina Kifnidi, Sumit Saha, Dirk Demuth, Haridarshan Patel, Brian Bressler

THE APPROPRIATENESS OF TESTING AND INTERPRETATION OF ANTI-TNF DRUG AND ANTIBODY CONCENTRATIONS: WHEN SHOULD THEY BE ORDERED, AND WHAT TO DO WITH THE RESULTS?

Gil Y. Melmed, Peter Irving, Gilaad G. Kaplan, Brian Bressler, Jennifer Jones, Patricia Kozuch, Miles P. Sparrow, Fernando Velayos, Leonard Baidoo, Adam Cheifetz, Shane Devlin, Laura Raffals, Niels Casteele, Diane R. Mould, William Sandborn, Corey A Siegel

Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)

Laurent Peyrin-Biroulet, James Lindsay, Brian Bressler

VEDOLIZUMAB OUTCOMES IN REAL-WORLD BIO-NAIVE ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS (EVOLVE) IN CANADA: TREATMENT PATTERNS, CLINICAL EFFECTIVENESS AND SAFETY

Brian Bressler, Marielle Bassel, Dara Stein, Mira Soni, Gabriela Radulescu, Astrid-Jane Greenup, Javaria Mona Khalid, Dirk Demuth

Item 1 - 8 / 12
1
2